Please assess the completion status of the following clinical trial:

Trial Title: An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18~* COVID-19 Confirmed Cases By Means of RT-PCR~* Oxygen saturation (SPO2) ≤ 93% OR respiratory rate ≥ 24~* At least one of the following: Calibrated contactless infrared forehead thermometry temperature of ≥37.8, cough, sputum production, nasal discharge, myalgia, headache or fatigue on admission.~* Time of onset of the symptoms should be acute ( Days ≤ 14)~Exclusion Criteria:~* Refusal to participate expressed by patient or legally authorized representative if they are present~* Patients with prolonged QT or PR intervals, Second or Third Degree heart block, Arrhythmias including torsade de pointes~* Patients using drugs with potential interaction with Hydroxychloroquine + Lopinavir/Ritonavir, Interferon-β 1a، Interferon-β 1b.~* Pregnant or lactating women.~* History of alcohol or drug addiction in the past 5 years.~* Blood ALT/AST levels \> 5 times the upper limit of normal on laboratory results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1a (Type: EXPERIMENTAL): None
- Hydroxychloroquine + Lopinavir / Ritonavir + Interferon-β 1b (Type: EXPERIMENTAL): None
- Control group: hydroxychloroquine + Lopinavir / Ritonavir (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).